Search PubMed⌕ Search

Biomedical subjects

N Gervasoni

Publications and source records attributed to N Gervasoni.

3 recordsLinked to original sources

A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study.

QUESTIONS UNDER STUDY/PRINCIPLES: We describe the proportion of severely depressed outpatients reaching complete remission at the different stages of a drug treatment algorithm. We compare several treatment options for SSRI (selective serotonin reuptake inhibitor) non-responders and test the feasibility of the algorithm in clinical conditions. METHODS: Patients with severe depressive disorders (ICD-10; MADRS > or = 25) admitted to an academic outpatient clinic were enrolled in this algorithm-guided sequential treatment protocol (starting with an SSRI and ending with a tricyclic, lithium, triodothyronine combination). The general principle of the algorithm was to boost the drug therapy in the event of non-response. RESULTS: 135 patients entered the study and 131 were eligible for analysis. From this group, 86 patients dropped out (65.6%), 40 reached complete remission (30.5%) and 5 patients did not reach remission at all (3.8%). In the 117 patients to whom a last observation carried forward approach was applied, the median improvement of the MADRS score was 48.0% (range -20.7%-100%), with 48.7% of patients considered responders, 23.1% partial responders and 28.2% non-responders. Median retention time was 8 weeks (range 2-34). CONCLUSIONS: This algorithm-guided antidepressant treatment was acceptable for clinicians and resulted in an elevated final response rate among study completers. However, the dropout rate was high, mainly due to treatment interruption or non-observance.

Adult↗

[Psychiatry].

During the year 2005 much of the attention was given to the debate on the risk of suicide during treatments with selective serotonin reuptake inhibitors. Our review concludes with a moderate increased risk of suicidal behaviour but not a risk of death by suicide. Caution, not panic, is indicated, particularly for children and adolescents given that, in this age group, benefits of these drugs have not been well established. We also report two synthesis concerning the latest developments in the fields of cognitive psychotherapy for depressive disorders (rather stimulating news) and of pharmacotherapy for borderline personality disorders (no breaking news).

Adolescent↗

Lithium dose prediction based on 24 hours single dose levels: a prospective evaluation.

The authors present the results of the utilization of a pharmacokinetic prediction test for lithium posology. Based on a single point (plasma lithium determination 24 h after a single dose) such a test aims to adapt the posology as soon as the second day of treatment rather than after one week as clinicians must wait for a steady state to be achieved. Built on the previous work of Perry, the test targeted the plasma lithium level at 0.8 +/- 0.1 mmol l(-1). Thirty-one patients took part in the study. There were two drop-out cases and the results were available for 29 patients: among them, 51% had their plasma level in the targeted zone. Although there was no control group, the prediction test often allowed us to use a higher dose than the usual fixed dose whose amount is limited by the risk of overdosing for the slower metabolizers.

Adult↗